EA199800104A1 - Способ лечения диабета - Google Patents

Способ лечения диабета

Info

Publication number
EA199800104A1
EA199800104A1 EA199800104A EA199800104A EA199800104A1 EA 199800104 A1 EA199800104 A1 EA 199800104A1 EA 199800104 A EA199800104 A EA 199800104A EA 199800104 A EA199800104 A EA 199800104A EA 199800104 A1 EA199800104 A1 EA 199800104A1
Authority
EA
Eurasian Patent Office
Prior art keywords
diabetes
treatment
type
obesity
patients
Prior art date
Application number
EA199800104A
Other languages
English (en)
Inventor
Томас В. Стефенз
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21692725&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA199800104(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of EA199800104A1 publication Critical patent/EA199800104A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Child & Adolescent Psychology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

В изобретении описан способ лечения диабета страдающих ожирением больных диабетом II типа. В частности, заявлен способ лечения больных, страдающих ожирением с диабетом II типа, с изменяющимся уровнем эндогенного лептина.Отчет о международном поиске был опубликован 1997.05.22.
EA199800104A 1995-06-30 1996-06-26 Способ лечения диабета EA199800104A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71895P 1995-06-30 1995-06-30
PCT/US1996/010983 WO1997002004A2 (en) 1995-06-30 1996-06-26 Methods for treating diabetes

Publications (1)

Publication Number Publication Date
EA199800104A1 true EA199800104A1 (ru) 1998-10-29

Family

ID=21692725

Family Applications (1)

Application Number Title Priority Date Filing Date
EA199800104A EA199800104A1 (ru) 1995-06-30 1996-06-26 Способ лечения диабета

Country Status (14)

Country Link
US (1) US5756461A (ru)
EP (1) EP0836479A2 (ru)
JP (1) JPH11508895A (ru)
KR (1) KR19990028388A (ru)
CN (1) CN1195293A (ru)
AU (1) AU695934B2 (ru)
CA (1) CA2225454A1 (ru)
CZ (1) CZ416797A3 (ru)
EA (1) EA199800104A1 (ru)
HU (1) HUP9802609A2 (ru)
IL (1) IL122718A0 (ru)
NO (1) NO976063L (ru)
PL (1) PL324284A1 (ru)
WO (1) WO1997002004A2 (ru)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001968A (en) 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US6350730B1 (en) 1994-08-17 2002-02-26 The Rockefeller University OB polypeptides and modified forms as modulators of body weight
US6429290B1 (en) 1994-08-17 2002-08-06 The Rockefeller University OB polypeptides, modified forms and derivatives
US6124448A (en) * 1994-08-17 2000-09-26 The Rockfeller University Nucleic acid primers and probes for the mammalian OB gene
US6048837A (en) * 1994-08-17 2000-04-11 The Rockefeller University OB polypeptides as modulators of body weight
US6471956B1 (en) 1994-08-17 2002-10-29 The Rockefeller University Ob polypeptides, modified forms and compositions thereto
ZA965346B (en) * 1995-06-30 1997-12-24 Lilly Co Eli Methods of treating neuropeptide Y-associated conditions.
EP0759441A3 (en) * 1995-06-30 1999-06-30 Eli Lilly And Company Methods of treating neuropeptide Y-associated conditions
US6001816A (en) * 1996-06-20 1999-12-14 Merck & Co., Inc. Gene therapy for leptin deficiency
US6277592B1 (en) 1996-07-31 2001-08-21 Purina Mills, Inc. Porcine leptin protein, nucleic acid sequences coding therefor and uses thereof
EP0956302A1 (en) * 1996-09-20 1999-11-17 Hoechst Aktiengesellschaft Use of leptin antagonists for treating insulin resistance in type ii diabetes
DK1629849T4 (en) * 1997-01-07 2017-12-04 Amylin Pharmaceuticals Llc Pharmaceutical compositions comprising exedins and agonists thereof
IL120733A0 (en) * 1997-04-29 1997-08-14 Yeda Res & Dev Leptin as an inhibitor of cell proliferation
HUP0003428A3 (en) * 1997-06-06 2001-12-28 Smithkline Beecham Plc Use of leptin antagonists for the treatment of diabetes
AU8671798A (en) * 1997-07-30 1999-02-22 Betagene, Inc. Methods and compositions relating to no-mediated cytotoxicity
ES2221717T3 (es) 1997-12-08 2005-01-01 Emd Lexigen Research Center Corp. Proteinas de fusion heterodimeras utiles para inmunoterapia dirigida e inmunoestimulacion general.
US5866547A (en) * 1998-01-20 1999-02-02 Beth Israel Deaconess Medical Center Methods of neuroendocrine regulation of affective disorders
US20030105294A1 (en) * 1998-02-25 2003-06-05 Stephen Gillies Enhancing the circulating half life of antibody-based fusion proteins
AU2893199A (en) * 1998-03-03 1999-09-20 Board Of Regents, The University Of Texas System Fatty acid-induced beta-cell apoptosis
JP4215857B2 (ja) * 1998-03-26 2009-01-28 裕 大村 学習・記憶能力改善剤
RU2229305C2 (ru) * 1998-04-15 2004-05-27 Лексиген Фармасьютикэлс Корпорейшн Усиление иммунных ответов, опосредованных белками, слитыми из антитела и цитокина, посредством совместного введения ингибитора ангиогенеза
US7208572B2 (en) 1998-08-21 2007-04-24 Albany Medical College Leptin-related peptides
US6777388B1 (en) 1998-08-21 2004-08-17 Clf Medical Technology Acceleration Program, Inc. Leptin-related peptides
JP2002526780A (ja) * 1998-10-02 2002-08-20 アムジエン・インコーポレーテツド レプチン処置に対する素因の決定方法
US6603058B1 (en) 1998-12-09 2003-08-05 Oklahoma Medical Research Foundation Non-human animal model for obesity and uses thereof
US6716810B1 (en) * 1998-12-09 2004-04-06 Eleanor Roosevelt Institute Composition and method for regulation of body weight and associated conditions
US20050272652A1 (en) 1999-03-29 2005-12-08 Gault Victor A Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
US6475984B2 (en) * 1999-04-29 2002-11-05 The Nemours Foundation Administration of leptin
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
HUP0202442A3 (en) * 1999-08-09 2005-01-28 Lexigen Pharmaceuticals Corp L Multiple cytokine-antibody complexes
AU2154401A (en) 1999-11-12 2001-05-30 Merck Patent Gmbh Erythropoietin forms with improved properties
ES2269366T3 (es) 2000-02-11 2007-04-01 Merck Patent Gmbh Mejoramiento de la vida media en circulacion de proteinas de fusion basadas en anticuerpos.
AU7172901A (en) * 2000-06-29 2002-01-14 Lexigen Pharm Corp Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents
DK1366067T3 (da) * 2001-03-07 2012-10-22 Merck Patent Gmbh Ekspressionsteknologi for proteiner indeholdende en hybrid isotype-antistof-enhed
WO2002079415A2 (en) * 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
RU2306320C9 (ru) * 2001-05-03 2008-01-27 Мерк Патент Гмбх Рекомбинантное опухолеспецифичное антитело (варианты) и его применение
DE60237100D1 (de) 2001-10-22 2010-09-02 Amgen Inc Verwendung von leptin zur behandlung von lipoatropr prädisposition gegenüber der behandlung
RU2312677C9 (ru) * 2001-12-04 2008-03-27 Мерк Патент Гмбх Иммуноцитокины с модулированной селективностью
US6899892B2 (en) * 2001-12-19 2005-05-31 Regents Of The University Of Minnesota Methods to reduce body fat
DK1572748T3 (da) * 2002-12-17 2010-08-23 Merck Patent Gmbh Humaniseret antistof (H14.18) af muse-14.18-antistof der binder til GD2 og dets fusionsprotein med IL-2
CN102174115B (zh) 2004-02-11 2014-05-14 安米林药品有限责任公司 具有可选择特性的杂合多肽
US8076288B2 (en) 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
NZ561361A (en) 2005-02-11 2010-02-26 Amylin Pharmaceuticals Inc GIP hybrid polypeptides with at least two hormonal activities
US8263545B2 (en) 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
ES2258923B1 (es) * 2005-02-23 2007-11-01 Universitat De Les Illes Balears Uso de la leptina para la prevencion del exceso de peso corporal y composicion que contiene leptina.
EP1922336B1 (en) 2005-08-11 2012-11-21 Amylin Pharmaceuticals, LLC Hybrid polypeptides with selectable properties
EP2330125A3 (en) 2005-08-11 2012-12-12 Amylin Pharmaceuticals, Inc. Hybrid polypeptides with selectable properties
US8227408B2 (en) * 2005-09-07 2012-07-24 Neurotez, Inc. Leptin as an anti-amyloidogenic biologic and methods for delaying the onset and reducing Alzheimer's disease-like pathology
US8497240B2 (en) 2006-08-17 2013-07-30 Amylin Pharmaceuticals, Llc DPP-IV resistant GIP hybrid polypeptides with selectable properties
KR20110028457A (ko) * 2008-05-21 2011-03-18 뉴로테즈 인코포레이티드 신경섬유 매듭과 연관된 신경변성 장애를 치료하는 방법
AU2009313562B2 (en) * 2008-11-04 2012-11-15 Neurotez, Inc. Leptin compositions and methods for treating progressive cognitive function disorders resulting from accumulation of neurofibrillary tangles and amlyoid beta
US20120071401A1 (en) 2009-04-10 2012-03-22 Amylin Pharamaceuticals, Inc. Amylin agonist compounds for estrogen-deficient mammals
CN102552225A (zh) * 2010-01-25 2012-07-11 四川省中医药科学院 四氢姜黄素的新用途
US20110218141A1 (en) * 2010-03-03 2011-09-08 Hamrick Mark W Leptin therapy to increase muscle mass and to treat muscle wasting conditions
ES2873253T3 (es) * 2010-09-28 2021-11-03 Amryt Pharmaceuticals Inc Leptinas altamente solubles
US10046013B2 (en) * 2011-03-08 2018-08-14 The Trustees Of The University Of Pennsylvania Engineered bacteria for oral delivery of glucoregulatory proteins
WO2013009539A1 (en) 2011-07-08 2013-01-17 Amylin Pharmaceuticals, Inc. Engineered polypeptides having enhanced duration of action and reduced immunogenicity
PT2900230T (pt) 2012-09-27 2018-11-26 Massachusetts Gen Hospital Compostos para o tratamento de obesidade e métodos de utilização dos mesmos
AU2014354831B2 (en) 2013-11-26 2017-10-26 The Children's Medical Center Corporation Compounds for the treatment of obesity and methods of use thereof
US20170209408A1 (en) 2014-04-03 2017-07-27 The Children's Medical Center Corporation Hsp90 inhibitors for the treatment of obesity and methods of use thereof
JP7139317B2 (ja) 2016-09-12 2022-09-20 アムリット・ファーマシューティカルズ・インコーポレイテッド 抗レプチン中和抗体を検出する方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6309853B1 (en) * 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof

Also Published As

Publication number Publication date
AU695934B2 (en) 1998-08-27
CZ416797A3 (cs) 1998-06-17
PL324284A1 (en) 1998-05-11
WO1997002004A2 (en) 1997-01-23
CA2225454A1 (en) 1997-01-23
HUP9802609A2 (hu) 1999-03-29
MX9800133A (es) 1998-03-29
NO976063L (no) 1998-02-16
US5756461A (en) 1998-05-26
KR19990028388A (ko) 1999-04-15
JPH11508895A (ja) 1999-08-03
WO1997002004A3 (en) 1997-05-22
CN1195293A (zh) 1998-10-07
IL122718A0 (en) 1998-08-16
NO976063D0 (no) 1997-12-23
EP0836479A2 (en) 1998-04-22
AU6479596A (en) 1997-02-05

Similar Documents

Publication Publication Date Title
EA199800104A1 (ru) Способ лечения диабета
ES2184127T3 (es) Derivados de sulfamato anticonvulsivos utiles para el tratamiento de la obesidad.
EP1231218A3 (en) An appetite-suppressing peptide, its compositions and use
EA199800857A1 (ru) Композиция для снятия боли и способ снятия боли
DE68904598D1 (de) Abwasserbehandlungsverfahren.
DE69732868D1 (de) Mittel gegen Juckreiz
EA200100572A1 (ru) Способ применения ингибитора циклооксигеназы-2 и одного или нескольких противоопухолевых лекарственных средств в качестве комбинированного способа лечебного воздействия при лечении неоплазии
WO2000035436A3 (en) Treatment of arthritis with mek inhibitors
KR930703001A (ko) 전신 홍반성낭창의 치료방법
DK0775007T3 (da) Blodbehandlingsindretning med forbedret udbytte, og som har en vinklet grænsestyreflade
NO970519D0 (no) Behandling av type II diabetes mellitus med amylinagonister
BG101966A (en) Application of 1l-agonist for the treatment of lack of urine retention
DE60139466D1 (de) Behandlung von diabetes
TR199900056T2 (xx) Leptin direncinin yeni tedavisi.
IT8323509A0 (it) Procedimento per trattare riso con pula unita ad esso e riso greggio, nonche' riso trattato con esso ottenuto.
DE69910425D1 (de) Neue therapeutische verwendung von nicergoline
NO982582L (no) Fremgangsmaate for behandling av smerte
PT869785E (pt) 4-hidroxicumarina-3-carboxamidas para o tratamento de diabetes mellitus nao insulinodependente
EA199700449A1 (ru) Способ предотвращения остеопороза
EA199800822A1 (ru) Способ лечения избыточной агрессии
NO20012849L (no) Ny terapeutisk anvendelse for hepariner med lav molekylvekt
ATE247467T1 (de) Neue therapeutische verwendung von 1,6-dimethyl- 8beta-hydroxymethyl-10alpha-methoxyergolin
IT1288184B1 (it) Procedimento per l'accorciamento del tempo di chiusura e dispositivo per l'attuazione del procedimento.
UA25164A (uk) Спосіб оперативhого лікуваhhя косоокості по в.і. ємчеhку
UA25165A (uk) Спосіб оперативhого лікуваhhя косоокості по в.і. ємчеhку